An investigational lung cancer drug from Novartis and Incyte could be on the market midway through next year after the FDA agreed to expedite development and review in a tough to treat form
In the context of unprecedented gene therapy clinical progress and mounting regulatory scrutiny, the inaugural Gene Therapy Analytical Development Summit will unite large pharma an
